Sign In
Last checked at 
15 Oct 2009 13:58
ο»Ώ
BEXIMCO PHARMACEUTICALS LTD.
15thΒ October, 2009
Extra-Ordinary General Meeting Statement
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announcesΒ that all resolutions put before shareholders at today's Extra-Ordinary General Meeting were duly passed.Β
Further information in respect of the Preference Share Issue announced on 10 September 2009, including progress on the Bangladesh SEC approval process, will be announced shortly.
For further enquiries please visitΒ www.beximco-pharma.comΒ or contact:
Β
Beximco Pharma
Nazmul Hassan, CEO
MD. ASAD ULLAH, FCS, Company Secretary
Tel: +880 2 861 9151, ext.2080
Β
Libertas Capital
Jakob Kinde / Anthony Rowland
Tel: +44 (0)20 7569 9650
Β
Financial Dynamics
Jonathan BirtΒ / Susan Quigley
Tel: +44 (0)20 7269 7169
Β
Notes to Editors
Β
About Beximco Pharmaceuticals Limited
Founded in 1976 and based inΒ Dhaka,Β Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site inΒ DhakaΒ and currently employs over 2,400 staff.
The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers inΒ Bangladesh, in regional markets such asΒ Sri Lanka,Β Nepal,Β Bhutan,Β Vietnam,Β CambodiaΒ andΒ MyanmarΒ and in other markets overseas, principally in East Africa,Β PacificΒ IslandΒ and Central American countries and South East Asia, includingΒ SingaporeΒ andΒ Hong Kong.
Follow the stocks
